IL2 and melanoma: Other examples include ORRs of 50% for the tumor matrix-binding IL-2 + TNFα immuno-cytokine mix Nidlegy/Daromun (which also improved recurrence-free survival for patients with locally advanced fully resectable melanoma) or single-agent matrix-binding IL-2 Darleukin (which also yielded a median survival of 905 days) (21, 30–33, 48), a median OS of 61.57 months for the GD2-targeted immuno-cytokine Hu14.18-IL2 which exceeded that achieved by i.v. administration (34–37), variable ORRs of 25-99.5% for i.t. injected IL-2, and ORR of up to 25% for recombinant IFNα.